SARS-CoV-2 Omicron Variant in Medicinal Chemistry Research

Volz, E.; Hill, V.; McCrone, J.T.; Price, A.; Jorgensen, D.; O’Toole, Á.; Southgate, J.; Johnson, R.; Jackson, B.; Nascimento, F.F.; Rey, S.M.; Nicholls, S.M.; Colquhoun, R.M.; da Silva Filipe, A.; Shepherd, J.; Pascall, D.J.; Shah, R.; Jesudason, N.; Li, K.; Jarrett, R.; Pacchiarini, N.; Bull, M.; Geidelberg, L.; Siveroni, I.; Goodfellow, I.; Loman, N.J.; Pybus, O.G.; Robertson, D.L.; Thomson, E.C.; Rambaut, A.; Connor, T.R.; Koshy, C.; Wise, E.; Cortes, N.; Lynch, J.; Kidd, S.; Mori, M.; Fairley, D.J.; Curran, T.; McKenna, J.P.; Adams, H.; Fraser, C.; Golubchik, T.; Bonsall, D.; Moore, C.; Caddy, S.L.; Khokhar, F.A.; Wantoch, M.; Reynolds, N.; Warne, B.; Maksimovic, J.; Spellman, K.; McCluggage, K.; John, M.; Beer, R.; Afifi, S.; Morgan, S.; Marchbank, A.; Price, A.; Kitchen, C.; Gulliver, H.; Merrick, I.; Southgate, J.; Guest, M.; Munn, R.; Workman, T.; Connor, T.R.; Fuller, W.; Bresner, C.; Snell, L.B.; Charalampous, T.; Nebbia, G.; Batra, R.; Edgeworth, J.; Robson, S.C.; Beckett, A.; Loveson, K.F.; Aanensen, D.M.; Underwood, A.P.; Yeats, C.A.; Abudahab, K.; Taylor, B.E.W.; Menegazzo, M.; Clark, G.; Smith, W.; Khakh, M.; Fleming, V.M.; Lister, M.M.; Howson-Wells, H.C.; Berry, L.; Boswell, T.; Joseph, A.; Willingham, I.; Bird, P.; Helmer, T.; Fallon, K.; Holmes, C.; Tang, J.; Raviprakash, V.; Campbell, S.; Sheriff, N.; Loose, M.W.; Holmes, N.; Moore, C.; Carlile, M.; Wright, V.; Sang, F.; Debebe, J.; Coll, F.; Signell, A.W.; Betancor, G.; Wilson, H.D.; Feltwell, T.; Houldcroft, C.J.; Eldirdiri, S.; Kenyon, A.; Davis, T.; Pybus, O.; du Plessis, L.; Zarebski, A.; Raghwani, J.; Kraemer, M.; Francois, S.; Attwood, S.; Vasylyeva, T.; Torok, M.E.; Hamilton, W.L.; Goodfellow, I.G.; Hall, G.; Jahun, A.S.; Chaudhry, Y.; Hosmillo, M.; Pinckert, M.L.; Georgana, I.; Yakovleva, A.; Meredith, L.W.; Moses, S.; Lowe, H.; Ryan, F.; Fisher, C.L.; Awan, A.R.; Boyes, J.; Breuer, J.; Harris, K.A.; Brown, J.R.; Shah, D.; Atkinson, L.; Lee, J.C.D.; Alcolea-Medina, A.; Moore, N.; Cortes, N.; Williams, R.; Chapman, M.R.; Levett, L.J.; Heaney, J.; Smith, D.L.; Bashton, M.; Young, G.R.; Allan, J.; Loh, J.; Randell, P.A.; Cox, A.; Madona, P.; Holmes, A.; Bolt, F.; Price, J.; Mookerjee, S.; Rowan, A.; Taylor, G.P.; Ragonnet-Cronin, M.; Nascimento, F.F.; Jorgensen, D.; Siveroni, I.; Johnson, R.; Boyd, O.; Geidelberg, L.; Volz, E.M.; Brunker, K.; Smollett, K.L.; Loman, N.J.; Quick, J.; McMurray, C.; Stockton, J.; Nicholls, S.; Rowe, W.; Poplawski, R.; Martinez-Nunez, R.T.; Mason, J.; Robinson, T.I.; O’Toole, E.; Watts, J.; Breen, C.; Cowell, A.; Ludden, C.; Sluga, G.; Machin, N.W.; Ahmad, S.S.Y.; George, R.P.; Halstead, F.; Sivaprakasam, V.; Thomson, E.C.; Shepherd, J.G.; Asamaphan, P.; Niebel, M.O.; Li, K.K.; Shah, R.N.; Jesudason, N.G.; Parr, Y.A.; Tong, L.; Broos, A.; Mair, D.; Nichols, J.; Carmichael, S.N.; Nomikou, K.; Aranday-Cortes, E.; Johnson, N.; Starinskij, I.; da Silva Filipe, A.; Robertson, D.L.; Orton, R.J.; Hughes, J.; Vattipally, S.; Singer, J.B.; Hale, A.D.; Macfarlane-Smith, L.R.; Harper, K.L.; Taha, Y.; Payne, B.A.I.; Burton-Fanning, S.; Waugh, S.; Collins, J.; Eltringham, G.; Templeton, K.E.; McHugh, M.P.; Dewar, R.; Wastenge, E.; Dervisevic, S.; Stanley, R.; Prakash, R.; Stuart, C.; Elumogo, N.; Sethi, D.K.; Meader, E.J.; Coupland, L.J.; Potter, W.; Graham, C.; Barton, E.; Padgett, D.; Scott, G.; Swindells, E.; Greenaway, J.; Nelson, A.; Yew, W.C.; Resende Silva, P.C.; Andersson, M.; Shaw, R.; Peto, T.; Justice, A.; Eyre, D.; Crooke, D.; Hoosdally, S.; Sloan, T.J.; Duckworth, N.; Walsh, S.; Chauhan, A.J.; Glaysher, S.; Bicknell, K.; Wyllie, S.; Butcher, E.; Elliott, S.; Lloyd, A.; Impey, R.; Levene, N.; Monaghan, L.; Bradley, D.T.; Allara, E.; Pearson, C.; Muir, P.; Vipond, I.B.; Hopes, R.; Pymont, H.M.; Hutchings, S.; Curran, M.D.; Parmar, S.; Lackenby, A.; Mbisa, T.; Platt, S.; Miah, S.; Bibby, D.; Manso, C.; Hubb, J.; Chand, M.; Dabrera, G.; Ramsay, M.; Bradshaw, D.; Thornton, A.; Myers, R.; Schaefer, U.; Groves, N.; Gallagher, E.; Lee, D.; Williams, D.; Ellaby, N.; Harrison, I.; Hartman, H.; Manesis, N.; Patel, V.; Bishop, C.; Chalker, V.; Osman, H.; Bosworth, A.; Robinson, E.; Holden, M.T.G.; Shaaban, S.; Birchley, A.; Adams, A.; Davies, A.; Gaskin, A.; Plimmer, A.; Gatica-Wilcox, B.; McKerr, C.; Moore, C.; Williams, C.; Heyburn, D.; De Lacy, E.; Hilvers, E.; Downing, F.; Shankar, G.; Jones, H.; Asad, H.; Coombes, J.; Watkins, J.; Evans, J.M.; Fina, L.; Gifford, L.; Gilbert, L.; Graham, L.; Perry, M.; Morgan, M.; Bull, M.; Cronin, M.; Pacchiarini, N.; Craine, N.; Jones, R.; Howe, R.; Corden, S.; Rey, S.; Kumziene-Summerhayes, S.; Taylor, S.; Cottrell, S.; Jones, S.; Edwards, S.; O’Grady, J.; Page, A.J.; Wain, J.; Webber, M.A.; Mather, A.E.; Baker, D.J.; Rudder, S.; Yasir, M.; Thomson, N.M.; Aydin, A.; Tedim, A.P.; Kay, G.L.; Trotter, A.J.; Gilroy, R.A.J.; Alikhan, N.F.; de Oliveira Martins, L.; Le-Viet, T.; Meadows, L.; Kolyva, A.; Diaz, M.; Bell, A.; Gutierrez, A.V.; Charles, I.G.; Adriaenssens, E.M.; Kingsley, R.A.; Casey, A.; Simpson, D.A.; Molnar, Z.; Thompson, T.; Acheson, E.; Masoli, J.A.H.; Knight, B.A.; Hattersley, A.; Ellard, S.; Auckland, C.; Mahungu, T.W.; Irish-Tavares, D.; Haque, T.; Bourgeois, Y.; Scarlett, G.P.; Partridge, D.G.; Raza, M.; Evans, C.; Johnson, K.; Liggett, S.; Baker, P.; Essex, S.; Lyons, R.A.; Caller, L.G.; Castellano, S.; Williams, R.J.; Kristiansen, M.; Roy, S.; Williams, C.A.; Dyal, P.L.; Tutill, H.J.; Panchbhaya, Y.N.; Forrest, L.M.; Niola, P.; Findlay, J.; Brooks, T.T.; Gavriil, A.; Mestek-Boukhibar, L.; Weeks, S.; Pandey, S.; Berry, L.; Jones, K.; Richter, A.; Beggs, A.; Smith, C.P.; Bucca, G.; Hesketh, A.R.; Harrison, E.M.; Peacock, S.J.; Palmer, S.; Churcher, C.M.; Bellis, K.L.; Girgis, S.T.; Naydenova, P.; Blane, B.; Sridhar, S.; Ruis, C.; Forrest, S.; Cormie, C.; Gill, H.K.; Dias, J.; Higginson, E.E.; Maes, M.; Young, J.; Kermack, L.M.; Hadjirin, N.F.; Aggarwal, D.; Griffith, L.; Swingler, T.; Davidson, R.K.; Rambaut, A.; Williams, T.; Balcazar, C.E.; Gallagher, M.D.; O’Toole, Á.; Rooke, S.; Jackson, B.; Colquhoun, R.; Ashworth, J.; Hill, V.; McCrone, J.T.; Scher, E.; Yu, X.; Williamson, K.A.; Stanton, T.D.; Michell, S.L.; Bewshea, C.M.; Temperton, B.; Michelsen, M.L.; Warwick-Dugdale, J.; Manley, R.; Farbos, A.; Harrison, J.W.; Sambles, C.M.; Studholme, D.J.; Jeffries, A.R.; Darby, A.C.; Hiscox, J.A.; Paterson, S.; Iturriza-Gomara, M.; Jackson, K.A.; Lucaci, A.O.; Vamos, E.E.; Hughes, M.; Rainbow, L.; Eccles, R.; Nelson, C.; Whitehead, M.; Turtle, L.; Haldenby, S.T.; Gregory, R.; Gemmell, M.; Kwiatkowski, D.; de Silva, T.I.; Smith, N.; Angyal, A.; Lindsey, B.B.; Groves, D.C.; Green, L.R.; Wang, D.; Freeman, T.M.; Parker, M.D.; Keeley, A.J.; Parsons, P.J.; Tucker, R.M.; Brown, R.; Wyles, M.; Constantinidou, C.; Unnikrishnan, M.; Ott, S.; Cheng, J.K.J.; Bridgewater, H.E.; Frost, L.R.; Taylor-Joyce, G.; Stark, R.; Baxter, L.; Alam, M.T.; Brown, P.E.; McClure, P.C.; Chappell, J.G.; Tsoleridis, T.; Ball, J.; Grammatopoulos, D.; Buck, D.; Todd, J.A.; Green, A.; Trebes, A.; MacIntyre-Cockett, G.; de Cesare, M.; Langford, C.; Alderton, A.; Amato, R.; Goncalves, S.; Jackson, D.K.; Johnston, I.; Sillitoe, J.; Palmer, S.; Lawniczak, M.; Berriman, M.; Danesh, J.; Livett, R.; Shirley, L.; Farr, B.; Quail, M.; Thurston, S.; Park, N.; Betteridge, E.; Weldon, D.; Goodwin, S.; Nelson, R.; Beaver, C.; Letchford, L.; Jackson, D.A.; Foulser, L.; McMinn, L.; Prestwood, L.; Kay, S.; Kane, L.; Dorman, M.J.; Martincorena, I.; Puethe, C.; Keatley, J.P.; Tonkin-Hill, G.; Smith, C.; Jamrozy, D.; Beale, M.A.; Patel, M.; Ariani, C.; Spencer-Chapman, M.; Drury, E.; Lo, S.; Rajatileka, S.; Scott, C.; James, K.; Buddenborg, S.K.; Berger, D.J.; Patel, G.; Garcia-Casado, M.V.; Dibling, T.; McGuigan, S.; Rogers, H.A.; Hunter, A.D.; Souster, E.; Neaverson, A.S. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell, 2021, 184(1), 64-75.e11.
[http://dx.doi.org/10.1016/j.cell.2020.11.020] [PMID: 33275900]

Weng, S.; Shang, J.; Cheng, Y.; Zhou, H.; Ji, C.; Yang, R.; Wu, A. Genetic differentiation and diversity of SARS-CoV-2 Omicron variant in its early outbreak. Biosafety Health, 2022, 4(3), 171-178.
[http://dx.doi.org/10.1016/j.bsheal.2022.04.004] [PMID: 35496653]

Sun, Y.; Lin, W.; Dong, W.; Xu, J. Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant. J. Biosafety Biosec., 2022, 4(1), 33-37.
[http://dx.doi.org/10.1016/j.jobb.2021.12.001] [PMID: 35005525]

Viana, R.; Moyo, S.; Amoako, D.G.; Tegally, H.; Scheepers, C.; Althaus, C.L.; Anyaneji, U.J.; Bester, P.A.; Boni, M.F.; Chand, M.; Choga, W.T.; Colquhoun, R.; Davids, M.; Deforche, K.; Doolabh, D.; du Plessis, L.; Engelbrecht, S.; Everatt, J.; Giandhari, J.; Giovanetti, M.; Hardie, D.; Hill, V.; Hsiao, N.Y.; Iranzadeh, A.; Ismail, A.; Joseph, C.; Joseph, R.; Koopile, L.; Kosakovsky Pond, S.L.; Kraemer, M.U.G.; Kuate-Lere, L.; Laguda-Akingba, O.; Lesetedi-Mafoko, O.; Lessells, R.J.; Lockman, S.; Lucaci, A.G.; Maharaj, A.; Mahlangu, B.; Maponga, T.; Mahlakwane, K.; Makatini, Z.; Marais, G.; Maruapula, D.; Masupu, K.; Matshaba, M.; Mayaphi, S.; Mbhele, N.; Mbulawa, M.B.; Mendes, A.; Mlisana, K.; Mnguni, A.; Mohale, T.; Moir, M.; Moruisi, K.; Mosepele, M.; Motsatsi, G.; Motswaledi, M.S.; Mphoyakgosi, T.; Msomi, N.; Mwangi, P.N.; Naidoo, Y.; Ntuli, N.; Nyaga, M.; Olubayo, L.; Pillay, S.; Radibe, B.; Ramphal, Y.; Ramphal, U.; San, J.E.; Scott, L.; Shapiro, R.; Singh, L.; Smith-Lawrence, P.; Stevens, W.; Strydom, A.; Subramoney, K.; Tebeila, N.; Tshiabuila, D.; Tsui, J.; van Wyk, S.; Weaver, S.; Wibmer, C.K.; Wilkinson, E.; Wolter, N.; Zarebski, A.E.; Zuze, B.; Goedhals, D.; Preiser, W.; Treurnicht, F.; Venter, M.; Williamson, C.; Pybus, O.G.; Bhiman, J.; Glass, A.; Martin, D.P.; Rambaut, A.; Gaseitsiwe, S.; von Gottberg, A.; de Oliveira, T. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 2022, 603(7902), 679-686.
[http://dx.doi.org/10.1038/s41586-022-04411-y] [PMID: 35042229]

WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available From: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern [Accessed on Jul 6, 2022].

WHO. WHO Coronavirus (COVID-19) Dashboard. Available From: https://covid19.who.int/

CDC. Omicron variant: What you need to know. Available From: https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html [Accessed on Jul 12, 2022].

Shah, M.; Woo, H.G. Omicron: A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies. Front. Immunol., 2022, 12, 830527.
[http://dx.doi.org/10.3389/fimmu.2021.830527] [PMID: 35140714]

GISAID. Tracking of variants., Available From: https://www.gisaid.org/hcov19-variants [Accessed on Jul 7, 2022].

WHO. Tracking SARS-CoV-2 variants. Available From: https://www.who.int/activities/tracking-SARS-CoV-2-variants [Accessed on Jul 6, 2022].

CDC. Science Brief: Omicron (B.1.1.529) Variant. Available From: https://www.cdc.gov/coronavirus/2019-ncov/science/sciencebriefs/scientific-brief-omicron-variant.html [Accessed on Jul 6, 2022].

Gobeil, S.M.C.; Henderson, R.; Stalls, V.; Janowska, K.; Huang, X.; May, A.; Speakman, M.; Beaudoin, E.; Manne, K.; Li, D.; Parks, R.; Barr, M.; Deyton, M.; Martin, M.; Mansouri, K.; Edwards, R.J.; Eaton, A.; Montefiori, D.C.; Sempowski, G.D.; Saunders, K.O.; Wiehe, K.; Williams, W.; Korber, B.; Haynes, B.F.; Acharya, P. Structural diversity of the SARS-CoV-2 Omicron spike. Mol. Cell, 2022, 82(11), 2050-2068.e6.
[http://dx.doi.org/10.1016/j.molcel.2022.03.028] [PMID: 35447081]

Du, P.; Gao, G.F.; Wang, Q. The mysterious origins of the Omicron variant of SARS-CoV-2. Innovation, 2022, 3(2), 100206.
[http://dx.doi.org/10.1016/j.xinn.2022.100206] [PMID: 35043101]

Wang, Q.; Anang, S.; Iketani, S.; Guo, Y.; Liu, L.; Katsamba, P.S.; Shapiro, L.; Ho, D.D.; Sodroski, J.G. Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. Cell Rep., 2022, 39(11), 110924.
[http://dx.doi.org/10.1016/j.celrep.2022.110924] [PMID: 35658975]

Chen, J.; Wang, R.; Gilby, N.B.; Wei, G.W. omicron variant (b.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J. Chem. Inf. Model., 2022, 62(2), 412-422.
[http://dx.doi.org/10.1021/acs.jcim.1c01451] [PMID: 34989238]

Fratev, F. R346K Mutation in the Mu Variant of SARS-CoV-2 Alters the Interactions with Monoclonal antibodies from Class 2: A free energy perturbation study. J. Chem. Inf. Model., 2022, 62(3), 627-631.
[http://dx.doi.org/10.1021/acs.jcim.1c01243] [PMID: 35072475]

Han, Y.; Yang, Z.; Hu, H.; Zhang, H.; Chen, L.; Li, K.; Kong, L.; Wang, Q.; Liu, B.; Wang, M.; Lin, J.; Chen, P.R. Covalently engineered protein minibinders with enhanced neutralization efficacy against escaping SARS-CoV-2 Variants. J. Am. Chem. Soc., 2022, 144(13), 5702-5707.
[http://dx.doi.org/10.1021/jacs.1c11554] [PMID: 35212528]

Greaney, A.J.; Starr, T.N.; Gilchuk, P.; Zost, S.J.; Binshtein, E.; Loes, A.N.; Hilton, S.K.; Huddleston, J.; Eguia, R.; Crawford, K.H.D.; Dingens, A.S.; Nargi, R.S.; Sutton, R.E.; Suryadevara, N.; Rothlauf, P.W.; Liu, Z.; Whelan, S.P.J.; Carnahan, R.H.; Crowe, J.E., Jr; Bloom, J.D. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe, 2021, 29(1), 44-57.e9.
[http://dx.doi.org/10.1016/j.chom.2020.11.007] [PMID: 33259788]

Harvey, W.T.; Carabelli, A.M.; Jackson, B.; Gupta, R.K.; Thomson, E.C.; Harrison, E.M.; Ludden, C.; Reeve, R.; Rambaut, A.; Peacock, S.J.; Robertson, D.L. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol., 2021, 19(7), 409-424.
[http://dx.doi.org/10.1038/s41579-021-00573-0] [PMID: 34075212]

Gao, S.J.; Guo, H.; Luo, G. Omicron variant (B.1.1.529) of SARS‐CoV‐2, a global urgent public health alert!. J. Med. Virol., 2022, 94(4), 1255-1256.
[http://dx.doi.org/10.1002/jmv.27491] [PMID: 34850421]

Karim, S.S.A.; Karim, Q.A. Omicron SARS-CoV-2 variant: A new chapter in the COVID-19 pandemic. Lancet, 2021, 398(10317), 2126-2128.
[http://dx.doi.org/10.1016/S0140-6736(21)02758-6] [PMID: 34871545]

Meng, B.; Abdullahi, A.; Ferreira, I.A.T.M.; Goonawardane, N.; Saito, A.; Kimura, I.; Yamasoba, D.; Gerber, P.P.; Fatihi, S.; Rathore, S.; Zepeda, S.K.; Papa, G.; Kemp, S.A.; Ikeda, T.; Toyoda, M.; Tan, T.S.; Kuramochi, J.; Mitsunaga, S.; Ueno, T.; Shirakawa, K.; Takaori-Kondo, A.; Brevini, T.; Mallery, D.L.; Charles, O.J.; Baker, S.; Dougan, G.; Hess, C.; Kingston, N.; Lehner, P.J.; Lyons, P.A.; Matheson, N.J.; Ouwehand, W.H.; Saunders, C.; Summers, C.; Thaventhiran, J.E.D.; Toshner, M.; Weekes, M.P.; Maxwell, P.; Shaw, A.; Bucke, A.; Calder, J.; Canna, L.; Domingo, J.; Elmer, A.; Fuller, S.; Harris, J.; Hewitt, S.; Kennet, J.; Jose, S.; Kourampa, J.; Meadows, A.; O’Brien, C.; Price, J.; Publico, C.; Rastall, R.; Ribeiro, C.; Rowlands, J.; Ruffolo, V.; Tordesillas, H.; Bullman, B.; Dunmore, B.J.; Gräf, S.; Hodgson, J.; Huang, C.; Hunter, K.; Jones, E.; Legchenko, E.; Matara, C.; Martin, J.; Mescia, F.; O’Donnell, C.; Pointon, L.; Shih, J.; Sutcliffe, R.; Tilly, T.; Treacy, C.; Tong, Z.; Wood, J.; Wylot, M.; Betancourt, A.; Bower, G.; Cossetti, C.; De Sa, A.; Epping, M.; Fawke, S.; Gleadall, N.; Grenfell, R.; Hinch, A.; Jackson, S.; Jarvis, I.; Krishna, B.; Nice, F.; Omarjee, O.; Perera, M.; Potts, M.; Richoz, N.; Romashova, V.; Stefanucci, L.; Strezlecki, M.; Turner, L.; De Bie, E.M.D.D.; Bunclark, K.; Josipovic, M.; Mackay, M.; Butcher, H.; Caputo, D.; Chandler, M.; Chinnery, P.; Clapham-Riley, D.; Dewhurst, E.; Fernandez, C.; Furlong, A.; Graves, B.; Gray, J.; Hein, S.; Ivers, T.; Le Gresley, E.; Linger, R.; Kasanicki, M.; King, R.; Kingston, N.; Meloy, S.; Moulton, A.; Muldoon, F.; Ovington, N.; Papadia, S.; Penkett, C.J.; Phelan, I.; Ranganath, V.; Paraschiv, R.; Sage, A.; Sambrook, J.; Scholtes, I.; Schon, K.; Stark, H.; Stirrups, K.E.; Townsend, P.; Walker, N.; Webster, J.; Butlertanaka, E.P.; Tanaka, Y.L.; Ito, J.; Uriu, K.; Kosugi, Y.; Suganami, M.; Oide, A.; Yokoyama, M.; Chiba, M.; Motozono, C.; Nasser, H.; Shimizu, R.; Kitazato, K.; Hasebe, H.; Irie, T.; Nakagawa, S.; Wu, J.; Takahashi, M.; Fukuhara, T.; Shimizu, K.; Tsushima, K.; Kubo, H.; Kazuma, Y.; Nomura, R.; Horisawa, Y.; Nagata, K.; Kawai, Y.; Yanagida, Y.; Tashiro, Y.; Tokunaga, K.; Ozono, S.; Kawabata, R.; Morizako, N.; Sadamasu, K.; Asakura, H.; Nagashima, M.; Yoshimura, K.; Cárdenas, P.; Muñoz, E.; Barragan, V.; Márquez, S.; Prado-Vivar, B.; Becerra-Wong, M.; Caravajal, M.; Trueba, G.; Rojas-Silva, P.; Grunauer, M.; Gutierrez, B.; Guadalupe, J.J.; Fernández-Cadena, J.C.; Andrade-Molina, D.; Baldeon, M.; Pinos, A.; Bowen, J.E.; Joshi, A.; Walls, A.C.; Jackson, L.; Martin, D.; Smith, K.G.C.; Bradley, J.; Briggs, J.A.G.; Choi, J.; Madissoon, E.; Meyer, K.B.; Mlcochova, P.; Ceron-Gutierrez, L.; Doffinger, R.; Teichmann, S.A.; Fisher, A.J.; Pizzuto, M.S.; de Marco, A.; Corti, D.; Hosmillo, M.; Lee, J.H.; James, L.C.; Thukral, L.; Veesler, D.; Sigal, A.; Sampaziotis, F.; Goodfellow, I.G.; Matheson, N.J.; Sato, K.; Gupta, R.K. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature, 2022, 603(7902), 706-714.
[http://dx.doi.org/10.1038/s41586-022-04474-x] [PMID: 35104837]

Zhang, J.; Cai, Y.; Lavine, C.L.; Peng, H.; Zhu, H.; Anand, K.; Tong, P.; Gautam, A.; Mayer, M.L.; Rits-Volloch, S.; Wang, S.; Sliz, P.; Wesemann, D.R.; Yang, W.; Seaman, M.S.; Lu, J.; Xiao, T.; Chen, B. Structural and functional impact by SARS-CoV-2 Omicron spike mutations. Cell Rep., 2022, 39(4), 110729.
[http://dx.doi.org/10.1016/j.celrep.2022.110729] [PMID: 35452593]

Hoffmann, M.; Krüger, N.; Schulz, S.; Cossmann, A.; Rocha, C.; Kempf, A.; Nehlmeier, I.; Graichen, L.; Moldenhauer, A.S.; Winkler, M.S.; Lier, M.; Dopfer-Jablonka, A.; Jäck, H.M.; Behrens, G.M.N.; Pöhlmann, S. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell, 2022, 185(3), 447-456.e11.
[http://dx.doi.org/10.1016/j.cell.2021.12.032] [PMID: 35026151]

Guo, H.; Gao, Y.; Li, T.; Li, T.; Lu, Y.; Zheng, L.; Liu, Y.; Yang, T.; Luo, F.; Song, S.; Wang, W.; Yang, X.; Nguyen, H.C.; Zhang, H.; Huang, A.; Jin, A.; Yang, H.; Rao, Z.; Ji, X. Structures of Omicron spike complexes and implications for neutralizing antibody development. Cell Rep., 2022, 39(5), 110770.
[http://dx.doi.org/10.1016/j.celrep.2022.110770] [PMID: 35477022]

Li, L.; Liao, H.; Meng, Y.; Li, W.; Han, P.; Liu, K.; Wang, Q.; Li, D.; Zhang, Y.; Wang, L.; Fan, Z.; Zhang, Y.; Wang, Q.; Zhao, X.; Sun, Y.; Huang, N.; Qi, J.; Gao, G.F. Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1. Cell, 2022, 185(16), 2952-2960.e10.
[http://dx.doi.org/10.1016/j.cell.2022.06.023] [PMID: 35809570]

ECDC. Epidemiological update: SARS-CoV-2 Omicron sublineages BA.4 and BA.5. Available From: https://www.ecdc.europa.eu/en/news-events/epidemiological-update-sars-cov-2-omicron-sub-lineages-ba4-and-ba5 [Accessed on Jul 12, 2022].

Koshikawa, T.; Miyoshi, H. High-resolution melting analysis to discriminate between the SARS-CoV-2 Omicron variants BA.1 and BA.2. Biochem. Biophys. Rep., 2022, 31, 101306.
[http://dx.doi.org/10.1016/j.bbrep.2022.101306] [PMID: 35791375]

Arora, P.; Kempf, A.; Nehlmeier, I.; Schulz, S.R.; Cossmann, A.; Stankov, M.V.; Jäck, H.M.; Behrens, G.M.N.; Pöhlmann, S.; Hoffmann, M. Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5. Lancet Infect. Dis., 2022, 22(8), 1117-1118.
[http://dx.doi.org/10.1016/S1473-3099(22)00422-4] [PMID: 35777385]

Schmidt, F.; Weisblum, Y.; Muecksch, F.; Hoffmann, H.H.; Michailidis, E.; Lorenzi, J.C.C.; Mendoza, P.; Rutkowska, M.; Bednarski, E.; Gaebler, C.; Agudelo, M.; Cho, A.; Wang, Z.; Gazumyan, A.; Cipolla, M.; Caskey, M.; Robbiani, D.F.; Nussenzweig, M.C.; Rice, C.M.; Hatziioannou, T.; Bieniasz, P.D. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med., 2020, 217(11), e20201181.
[http://dx.doi.org/10.1084/jem.20201181] [PMID: 32692348]

Dhawan, M.; Saied, A.A.; Emran, T.B.; Choudhary, O.P. Emergence of omicron variant’s sublineages BA.4 and BA.5: Risks assessment and possible countermeasures. New Microbes New Infect., 2022, 48, 100997.
[http://dx.doi.org/10.1016/j.nmni.2022.100997] [PMID: 35873063]

Mader, A.L.; Tydykov, L.; Glück, V.; Bertok, M.; Weidlich, T.; Gottwald, C.; Stefl, A.; Vogel, M.; Plentz, A.; Köstler, J.; Salzberger, B.; Wenzel, J.J.; Niller, H.H.; Jantsch, J.; Wagner, R.; Schmidt, B.; Glück, T.; Gessner, A.; Peterhoff, D. Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals. iScience, 2022, 25(4), 104076.
[http://dx.doi.org/10.1016/j.isci.2022.104076] [PMID: 35309727]

Tuekprakhon, A.; Nutalai, R.; Dijokaite-Guraliuc, A.; Zhou, D.; Ginn, H.M.; Selvaraj, M.; Liu, C.; Mentzer, A.J.; Supasa, P.; Duyvesteyn, H.M.E.; Das, R.; Skelly, D.; Ritter, T.G.; Amini, A.; Bibi, S.; Adele, S.; Johnson, S.A.; Constantinides, B.; Webster, H.; Temperton, N.; Klenerman, P.; Barnes, E.; Dunachie, S.J.; Crook, D.; Pollard, A.J.; Lambe, T.; Goulder, P.; Paterson, N.G.; Williams, M.A.; Hall, D.R.; Fry, E.E.; Huo, J.; Mongkolsapaya, J.; Ren, J.; Stuart, D.I.; Screaton, G.R.; Conlon, C.; Deeks, A.; Frater, J.; Frending, L.; Gardiner, S.; Jämsén, A.; Jeffery, K.; Malone, T.; Phillips, E.; Rothwell, L.; Stafford, L. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell, 2022, 185(14), 2422-2433.e13.
[http://dx.doi.org/10.1016/j.cell.2022.06.005] [PMID: 35772405]

Huang, M.; Wu, L.; Zheng, A.; Xie, Y.; He, Q.; Rong, X.; Han, P.; Du, P.; Han, P.; Zhang, Z.; Zhao, R.; Jia, Y.; Li, L.; Bai, B.; Hu, Z.; Hu, S.; Niu, S.; Hu, Y.; Liu, H.; Liu, B.; Cui, K.; Li, W.; Zhao, X.; Liu, K.; Qi, J.; Wang, Q.; Gao, G.F. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. Immunity, 2022, 55(8), 1501-1514.e3.
[http://dx.doi.org/10.1016/j.immuni.2022.06.005] [PMID: 35777362]

Stalls, V.; Lindenberger, J.; Gobeil, S.M.C.; Henderson, R.; Parks, R.; Barr, M.; Deyton, M.; Martin, M.; Janowska, K.; Huang, X.; May, A.; Speakman, M.; Beaudoin, E.; Kraft, B.; Lu, X.; Edwards, R.J.; Eaton, A.; Montefiori, D.C.; Williams, W.B.; Saunders, K.O.; Wiehe, K.; Haynes, B.F.; Acharya, P. Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike. Cell Rep., 2022, 39(13), 111009.
[http://dx.doi.org/10.1016/j.celrep.2022.111009] [PMID: 35732171]

Mohapatra, R.K.; Kandi, V.; Sarangi, A.K.; Verma, S.; Tuli, H.S.; Chakraborty, S.; Chakraborty, C.; Dhama, K. The recently emerged BA.4 and BA.5 lineages of Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic – Correspondence. Int. J. Surg., 2022, 103, 106698.
[http://dx.doi.org/10.1016/j.ijsu.2022.106698] [PMID: 35690362]

Gordon, D.E.; Jang, G.M.; Bouhaddou, M.; Xu, J.; Obernier, K.; White, K.M.; O’Meara, M.J.; Rezelj, V.V.; Guo, J.Z.; Swaney, D.L.; Tummino, T.A.; Hüttenhain, R.; Kaake, R.M.; Richards, A.L.; Tutuncuoglu, B.; Foussard, H.; Batra, J.; Haas, K.; Modak, M.; Kim, M.; Haas, P.; Polacco, B.J.; Braberg, H.; Fabius, J.M.; Eckhardt, M.; Soucheray, M.; Bennett, M.J.; Cakir, M.; McGregor, M.J.; Li, Q.; Meyer, B.; Roesch, F.; Vallet, T.; Mac Kain, A.; Miorin, L.; Moreno, E.; Naing, Z.Z.C.; Zhou, Y.; Peng, S.; Shi, Y.; Zhang, Z.; Shen, W.; Kirby, I.T.; Melnyk, J.E.; Chorba, J.S.; Lou, K.; Dai, S.A.; Barrio-Hernandez, I.; Memon, D.; Hernandez-Armenta, C.; Lyu, J.; Mathy, C.J.P.; Perica, T.; Pilla, K.B.; Ganesan, S.J.; Saltzberg, D.J.; Rakesh, R.; Liu, X.; Rosenthal, S.B.; Calviello, L.; Venkataramanan, S.; Liboy-Lugo, J.; Lin, Y.; Huang, X.P.; Liu, Y.F.; Wankowicz, S.A.; Bohn, M.; Safari, M.; Ugur, F.S.; Koh, C.; Savar, N.S.; Tran, Q.D.; Shengjuler, D.; Fletcher, S.J.; O’Neal, M.C.; Cai, Y.; Chang, J.C.J.; Broadhurst, D.J.; Klippsten, S.; Sharp, P.P.; Wenzell, N.A.; Kuzuoglu-Ozturk, D.; Wang, H.Y.; Trenker, R.; Young, J.M.; Cavero, D.A.; Hiatt, J.; Roth, T.L.; Rathore, U.; Subramanian, A.; Noack, J.; Hubert, M.; Stroud, R.M.; Frankel, A.D.; Rosenberg, O.S.; Verba, K.A.; Agard, D.A.; Ott, M.; Emerman, M.; Jura, N.; von Zastrow, M.; Verdin, E.; Ashworth, A.; Schwartz, O.; d’Enfert, C.; Mukherjee, S.; Jacobson, M.; Malik, H.S.; Fujimori, D.G.; Ideker, T.; Craik, C.S.; Floor, S.N.; Fraser, J.S.; Gross, J.D.; Sali, A.; Roth, B.L.; Ruggero, D.; Taunton, J.; Kortemme, T.; Beltrao, P.; Vignuzzi, M.; García-Sastre, A.; Shokat, K.M.; Shoichet, B.K.; Krogan, N.J.A. SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing. Nat., 2020, 583, 459-468.

Braga, S.; Schmidt, A. Clinical and cytogenetic spectrum of duplication 3p. Eur. J. Pediatr., 1982, 138(2), 195-197.
[http://dx.doi.org/10.1007/BF00441155] [PMID: 7094943]

Chan, J.F.W.; Kok, K.H.; Zhu, Z.; Chu, H.; To, K.K.W.; Yuan, S.; Yuen, K.Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect., 2020, 9(1), 221-236.
[http://dx.doi.org/10.1080/22221751.2020.1719902] [PMID: 31987001]

Fehr, A.R.; Perlman, S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol. Biol., 2015, 1282, 1-23.
[http://dx.doi.org/10.1007/978-1-4939-2438-7_1]

Zhang, J.; Xiao, T.; Cai, Y.; Chen, B. Structure of SARS-CoV-2 spike protein. Curr. Opin. Virol., 2021, 50, 173-182.
[http://dx.doi.org/10.1016/j.coviro.2021.08.010] [PMID: 34534731]

Duart, G.; García-Murria, M.J.; Grau, B.; Acosta-Cáceres, J.M.; Martínez-Gil, L.; Mingarro, I. SARS-CoV-2 envelope protein topology in eukaryotic membranes. Open Biol., 2020, 10(9), 200209.
[http://dx.doi.org/10.1098/rsob.200209] [PMID: 32898469]

Al-Qaaneh, A.M.; Alshammari, T.; Aldahhan, R.; Aldossary, H.; Alkhalifah, Z.A.; Borgio, J.F. Genome composition and genetic characterization of SARS-CoV-2. Saudi J. Biol. Sci., 2021, 28(3), 1978-1989.
[http://dx.doi.org/10.1016/j.sjbs.2020.12.053] [PMID: 33519278]

Bianchi, M.; Benvenuto, D.; Giovanetti, M.; Angeletti, S.; Ciccozzi, M.; Pascarella, S. Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics? Biomed Res. Int., 2020.

Zeng, W.; Liu, G.; Ma, H.; Zhao, D.; Yang, Y.; Liu, M.; Mohammed, A.; Zhao, C.; Yang, Y.; Xie, J.; Ding, C.; Ma, X.; Weng, J.; Gao, Y.; He, H.; Jin, T. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem. Biophys. Res. Commun., 2020, 527(3), 618-623.
[http://dx.doi.org/10.1016/j.bbrc.2020.04.136] [PMID: 32416961]

Liu, S.; Leng, C.; Lien, S.; Chi, H.; Huang, C.; Lin, C.; Lian, W.; Chen, C.; Hsieh, S.; Chong, P. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine, 2006, 24(16), 3100-3108.
[http://dx.doi.org/10.1016/j.vaccine.2006.01.058] [PMID: 16494977]

Silva, L.R.; da Silva Santos-Júnior, P.F.; de Andrade Brandão, J.; Anderson, L.; Bassi, Ê.J.; Xavier de Araújo-Júnior, J.; Cardoso, S.H.; da Silva-Júnior, E.F. Druggable targets from coronaviruses for designing new antiviral drugs. Bioorg. Med. Chem., 2020, 28(22), 115745.
[http://dx.doi.org/10.1016/j.bmc.2020.115745] [PMID: 33007557]

Anand, K.; Ziebuhr, J.; Wadhwani, P.; Mesters, J.R.; Hilgenfeld, R.; Qamar, T. Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs. Science, 2003, 300, 1763-1767.

Tahir ul Qamar, M.; Alqahtani, S.M.; Alamri, M.A.; Chen, L.L. Structural Basis of SARS-CoV-2 3CLpro and Anti-COVID-19 Drug Discovery from Medicinal Plants. J. Pharm. Anal., 2020, 10(4), 313-319.

Perlman, S.; Netland, J. Coronaviruses post-SARS: Update on replication and pathogenesis. Nat. Rev. Microbiol., 2009, 7(6), 439-450.
[http://dx.doi.org/10.1038/nrmicro2147] [PMID: 19430490]

Tomar, S.; Johnston, M.L.; St John, S.E.; Osswald, H.L.; Nyalapatla, P.R.; Paul, L.N.; Ghosh, A.K.; Denison, M.R.; Mesecar, A.D. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): Implications for nsp5 regulation and the development of antivirals. J. Biol. Chem., 2015, 290(32), 19403-19422.
[http://dx.doi.org/10.1074/jbc.M115.651463] [PMID: 26055715]

Harcourt, B.H.; Jukneliene, D.; Kanjanahaluethai, A.; Bechill, J.; Severson, K.M.; Smith, C.M.; Rota, P.A.; Baker, S.C. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J. Virol., 2004, 78(24), 13600-13612.
[http://dx.doi.org/10.1128/JVI.78.24.13600-13612.2004] [PMID: 15564471]

Báez-Santos, Y.M.; St John, S.E.; Mesecar, A.D. The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antiviral Res., 2015, 115, 21-38.
[http://dx.doi.org/10.1016/j.antiviral.2014.12.015] [PMID: 25554382]

Barretto, N.; Jukneliene, D.; Ratia, K.; Chen, Z.; Mesecar, A.D.; Baker, S.C. Deubiquitinating activity of the SARS-CoV papain-like protease. Adv. Exp. Med. Biol., 2006, 581, 37-41.
[http://dx.doi.org/10.1007/978-0-387-33012-9_5] [PMID: 17037501]

Lindner, H.A.; Fotouhi-Ardakani, N.; Lytvyn, V.; Lachance, P.; Sulea, T.; Ménard, R. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J. Virol., 2005, 79(24), 15199-15208.
[http://dx.doi.org/10.1128/JVI.79.24.15199-15208.2005] [PMID: 16306591]

Frieman, M.; Ratia, K.; Johnston, R.E.; Mesecar, A.D.; Baric, R.S. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J. Virol., 2009, 83(13), 6689-6705.
[http://dx.doi.org/10.1128/JVI.02220-08] [PMID: 19369340]

Ratia, K.; Saikatendu, K.S.; Santarsiero, B.D.; Barretto, N.; Baker, S.C.; Stevens, R.C.; Mesecar, A.D. Severe acute respiratory syndrome coronavirus papain-like protease: Structure of a viral deubiquitinating enzyme. Proc. Natl. Acad. Sci. USA, 2006, 103(15), 5717-5722.
[http://dx.doi.org/10.1073/pnas.0510851103] [PMID: 16581910]

Lei, J.; Mesters, J.R.; Drosten, C.; Anemüller, S.; Ma, Q.; Hilgenfeld, R. Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features. Antiviral Res., 2014, 109, 72-82.
[http://dx.doi.org/10.1016/j.antiviral.2014.06.011] [PMID: 24992731]

Tan, H.; Hu, Y.; Jadhav, P.; Tan, B.; Wang, J. Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease. J. Med. Chem., 2022, 65(11), 7561-7580.
[http://dx.doi.org/10.1021/acs.jmedchem.2c00303] [PMID: 35620927]

dos Santos Nascimento, I.J.; da Silva-Júnior, E.F.; de Aquino, T.M. Molecular Modeling Targeting Transmembrane Serine Protease 2 (TMPRSS2) as an Alternative Drug Target Against Coronaviruses. Curr. Drug Targets, 2022, 23(3), 240-259.
[http://dx.doi.org/10.2174/1389450122666210809090909] [PMID: 34370633]

Santos-Júnior, P.F. da S.; Araújo-Júnior, J.X. Silva-Júnior. Peptidomimetic and Peptide-Derived Against 3CLpro from Coronaviruses.Pharmaceut. Target. Coronaviruses; Santos-Júnior, P.F. da S.; de Araújo-Júnior, J.X.; da Silva-Júnior, E.F., Eds.; Bentham science publishers, 2022, pp. 158-188.
[http://dx.doi.org/10.2174/9789815051308122010007]

Nascimento, I.J. dos S.; de Aquino, T.M.; da Silva-Júnior, E.F. Structure-Based Drug Discovery Approaches Applied to SARSCoV-2 (COVID-19).Pharmaceuticals for Targeting Coronaviruses; Nascimento, I.J. dos S.; de Aquino, T.M.; da Silva-Júnior, E.F., Eds.; Bentham science publishers, 2022, pp. 1-61.
[http://dx.doi.org/10.2174/9789815051308122010003]

Fernando da Silva Santos-Junior, P.; Jose dos Santos Nascimento, I.; Mendonca de Aquino, T.; Xavier de Araujo-Junior, J.; Ferreira da Silva-Junior, E. Drug discovery strategies against emerging coronaviruses: A global threat.Frontiers in Anti-Infective Drug Discovery; , 2020, pp. 35-90.
[http://dx.doi.org/10.2174/9789811412387120080004]

dos Santos Nascimento, I.J.; de Aquino, T.M.; da Silva-Júnior, E.F. Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections. Curr. Med. Chem., 2021, 28(15), 2887-2942.
[http://dx.doi.org/10.2174/1875533XMTA5rMDYp5] [PMID: 32787752]

Milken, I. COVID-19 Treatment and Vaccine Tracker. Available From: https://covid-19tracker.milkeninstitute.org/ [Accessed on Jul 8, 2022].

Kato, Y.; Nishiyama, K.; Nishimura, A.; Noda, T.; Okabe, K.; Kusakabe, T.; Kanda, Y.; Nishida, M. Drug repurposing for the treatment of COVID-19. J. Pharmacol. Sci., 2022, 149(3), 108-114.
[http://dx.doi.org/10.1016/j.jphs.2022.04.007] [PMID: 35641023]

Kumar, S.; Kovalenko, S.; Bhardwaj, S.; Sethi, A.; Gorobets, N.Y.; Desenko, S.M.; Poonam; Rathi, B. Drug repurposing against SARS-CoV-2 using computational approaches. Drug Discov. Today, 2022, 27(7), 2015-2027.
[http://dx.doi.org/10.1016/j.drudis.2022.02.004] [PMID: 35151891]

NIH. Antiviral Therapy | COVID-19 Treatment Guidelines. Available From: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ [Accessed on Jul 8, 2022].

Jie, X.; Hongmei, Y.; Ping, F.; Kuikui, Z.; Bohan, Y.; Rui, M. Beneficial effect of Arbidol in the management of COVID-19 infection. Aging, 2021, 13(7), 9253-9264.
[http://dx.doi.org/10.18632/aging.202867] [PMID: 33811756]

Manabe, T.; Kambayashi, D.; Akatsu, H.; Kudo, K. Favipiravir for the treatment of patients with COVID-19: A systematic review and meta-analysis. BMC Infect. Dis., 2021, 21(1), 489.
[http://dx.doi.org/10.1186/s12879-021-06164-x] [PMID: 34044777]

Pfizer.. Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults. Available From: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-starts-global-phase-23-epic-pep-study-novel-covid-19 [Accessed on Jul 10, 2022].

Halford, B. Pills to End the Pandemic. C&EN Glob. Interprise, 2021, 99, 44-45.

Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis. Available From: https://ir.ateapharma.com/news-releases/news-release-details/ateas-527-oral-antiviral-drug-candidate-reduces-viral/ [Accessed on Jul 10, 2022].

Saputri, D.S.; Li, S.; van Eerden, F.J.; Rozewicki, J.; Xu, Z.; Ismanto, H.S.; Davila, A.; Teraguchi, S.; Katoh, K.; Standley, D.M. Flexible, Functional, and Familiar: Characteristics of SARS-CoV-2 Spike Protein Evolution. Front. Microbiol., 2020, 11, 2112.
[http://dx.doi.org/10.3389/fmicb.2020.02112] [PMID: 33042039]

Khateeb, J.; Li, Y.; Zhang, H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit. Care, 2021, 25(1), 244.
[http://dx.doi.org/10.1186/s13054-021-03662-x] [PMID: 34253247]

Qu, X.X.; Hao, P.; Song, X.J.; Jiang, S.M.; Liu, Y.X.; Wang, P.G.; Rao, X.; Song, H.D.; Wang, S.Y.; Zuo, Y.; Zheng, A.H.; Luo, M.; Wang, H.L.; Deng, F.; Wang, H.Z.; Hu, Z.H.; Ding, M.X.; Zhao, G.P.; Deng, H.K. Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy. J. Biol. Chem., 2005, 280(33), 29588-29595.
[http://dx.doi.org/10.1074/jbc.M500662200] [PMID: 15980414]

Song, H.D.; Tu, C.C.; Zhang, G.W.; Wang, S.Y.; Zheng, K.; Lei, L.C.; Chen, Q.X.; Gao, Y.W.; Zhou, H.Q.; Xiang, H.; Zheng, H.J.; Chern, S.W.W.; Cheng, F.; Pan, C.M.; Xuan, H.; Chen, S.J.; Luo, H.M.; Zhou, D.H.; Liu, Y.F.; He, J.F.; Qin, P.Z.; Li, L.H.; Ren, Y.Q.; Liang, W.J.; Yu, Y.D.; Anderson, L.; Wang, M.; Xu, R.H.; Wu, X.W.; Zheng, H.Y.; Chen, J.D.; Liang, G.; Gao, Y.; Liao, M.; Fang, L.; Jiang, L.Y.; Li, H.; Chen, F.; Di, B.; He, L.J.; Lin, J.Y.; Tong, S.; Kong, X.; Du, L.; Hao, P.; Tang, H.; Bernini, A.; Yu, X.J.; Spiga, O.; Guo, Z.M.; Pan, H.Y.; He, W.Z.; Manuguerra, J.C.; Fontanet, A.; Danchin, A.; Niccolai, N.; Li, Y.X.; Wu, C.I.; Zhao, G.P. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc. Natl. Acad. Sci. USA, 2005, 102(7), 2430-2435.
[http://dx.doi.org/10.1073/pnas.0409608102] [PMID: 15695582]

Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; Müller, M.A.; Drosten, C.; Pöhlmann, S. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181(2), 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]

Walls, A.C.; Park, Y.J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Veesler, D. Structure, function, and antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 2020, 183(6), 1735.
[http://dx.doi.org/10.1016/j.cell.2020.11.032] [PMID: 33306958]

Chen, J.; Wei, G.W. Omicron BA.2 (B.1.1.529.2): High potential for becoming the next dominant variant. J. Phys. Chem. Lett., 2022, 13(17), 3840-3849.
[http://dx.doi.org/10.1021/acs.jpclett.2c00469] [PMID: 35467344]

Socher, E.; Heger, L.; Paulsen, F.; Zunke, F.; Arnold, P. Molecular dynamics simulations of the delta and omicron SARS-CoV-2 spike – ACE2 complexes reveal distinct changes between both variants. Comput. Struct. Biotechnol. J., 2022, 20, 1168-1176.
[http://dx.doi.org/10.1016/j.csbj.2022.02.015] [PMID: 35251533]

Verkhivker, G.M.; Agajanian, S.; Kassab, R.; Krishnan, K. Landscape-based protein stability analysis and network modeling of multiple conformational states of the SARS-CoV-2 Spike D614G Mutant: Conformational plasticity and frustration-induced allostery as energetic drivers of highly transmissible spike variants. J. Chem. Inf. Model., 2022, 62(8), 1956-1978.
[http://dx.doi.org/10.1021/acs.jcim.2c00124] [PMID: 35377633]

Jawad, B.; Adhikari, P.; Podgornik, R.; Ching, W.Y. Binding interactions between receptor-binding domain of spike protein and human angiotensin converting enzyme-2 in omicron variant. J. Phys. Chem. Lett., 2022, 13(17), 3915-3921.
[http://dx.doi.org/10.1021/acs.jpclett.2c00423] [PMID: 35481766]

Hwang, S.; Baek, S.H.; Park, D. Interaction analysis of the spike protein of delta and omicron variants of SARS-CoV-2 with hACE2 and eight monoclonal antibodies using the fragment molecular orbital method. J. Chem. Inf. Model., 2022, 62(7), 1771-1782.
[http://dx.doi.org/10.1021/acs.jcim.2c00100] [PMID: 35312321]

Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.-L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation. Science, 2020, 367(6483), 1260-1263.

Yuan, Y.; Cao, D.; Zhang, Y.; Ma, J.; Qi, J.; Wang, Q.; Lu, G.; Wu, Y.; Yan, J.; Shi, Y.; Zhang, X.; Gao, G.F. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun., 2017, 8(1), 15092.
[http://dx.doi.org/10.1038/ncomms15092] [PMID: 28393837]

Khan, A.; Waris, H.; Rafique, M.; Suleman, M.; Mohammad, A.; Ali, S.S.; Khan, T.; Waheed, Y.; Liao, C.; Wei, D.Q. The Omicron (B.1.1.529) variant of SARS-CoV-2 binds to the hACE2 receptor more strongly and escapes the antibody response: Insights from structural and simulation data. Int. J. Biol. Macromol., 2022, 200, 438-448.
[http://dx.doi.org/10.1016/j.ijbiomac.2022.01.059] [PMID: 35063482]

Mansbach, R.A.; Chakraborty, S.; Nguyen, K.; Montefiori, D.C.; Korber, B.; Gnanakaran, S. The SARS-CoV-2 Spike variant D614G favors an open conformational state. Sci. Adv., 2021, 7(16), eabf3671.
[http://dx.doi.org/10.1126/sciadv.abf3671] [PMID: 33863729]

Krause, P.R.; Fleming, T.R.; Longini, I.M.; Peto, R.; Briand, S.; Heymann, D.L.; Beral, V.; Snape, M.D.; Rees, H.; Ropero, A.M.; Balicer, R.D.; Cramer, J.P.; Muñoz-Fontela, C.; Gruber, M.; Gaspar, R.; Singh, J.A.; Subbarao, K.; Van Kerkhove, M.D.; Swaminathan, S.; Ryan, M.J.; Henao-Restrepo, A.M. SARS-CoV-2 Variants and Vaccines. N. Engl. J. Med., 2021, 385(2), 179-186.
[http://dx.doi.org/10.1056/NEJMsr2105280] [PMID: 34161052]

Shah, M.; Woo, H.G. Molecular Perspectives of SARS-CoV-2: Pathology, immune evasion, and therapeutic interventions. Mol. Cells, 2021, 44(6), 408-421.
[http://dx.doi.org/10.14348/molcells.2021.0026] [PMID: 34059561]

Lan, J.; Ge, J.; Yu, J.; Shan, S.; Zhou, H.; Fan, S.; Zhang, Q.; Shi, X.; Wang, Q.; Zhang, L.; Wang, X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 2020, 581(7807), 215-220.
[http://dx.doi.org/10.1038/s41586-020-2180-5] [PMID: 32225176]

Shang, J.; Ye, G.; Shi, K.; Wan, Y.; Luo, C.; Aihara, H.; Geng, Q.; Auerbach, A.; Li, F. Structural basis of receptor recognition by SARS-CoV-2. Nature, 2020, 581(7807), 221-224.
[http://dx.doi.org/10.1038/s41586-020-2179-y] [PMID: 32225175]

Hu, H.; Li, L.; Kao, R.Y.; Kou, B.; Wang, Z.; Zhang, L.; Zhang, H.; Hao, Z.; Tsui, W.H.; Ni, A.; Cui, L.; Fan, B.; Guo, F.; Rao, S.; Jiang, C.; Li, Q.; Sun, M.; He, W.; Liu, G. Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. J. Comb. Chem., 2005, 7(5), 648-656.
[http://dx.doi.org/10.1021/cc0500607] [PMID: 16153058]

Han, D.P.; Penn-Nicholson, A.; Cho, M.W. Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. Virology, 2006, 350(1), 15-25.
[http://dx.doi.org/10.1016/j.virol.2006.01.029] [PMID: 16510163]

Shah, M.; Ung Moon, S.; Hyun Kim, J.; Thanh Thao, T.; Goo Woo, H. SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. Comput. Struct. Biotechnol. J., 2022, 20, 2042-2056.
[http://dx.doi.org/10.1016/j.csbj.2022.04.030] [PMID: 35495107]

Liu, Z.; Xu, W.; Xia, S.; Gu, C.; Wang, X.; Wang, Q.; Zhou, J.; Wu, Y.; Cai, X.; Qu, D.; Ying, T.; Xie, Y.; Lu, L.; Yuan, Z.; Jiang, S. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct. Target. Ther., 2020, 5(1), 282.
[http://dx.doi.org/10.1038/s41392-020-00402-5] [PMID: 33247109]

Yang, J.; Wang, W.; Chen, Z.; Lu, S.; Yang, F.; Bi, Z.; Bao, L.; Mo, F.; Li, X.; Huang, Y.; Hong, W.; Yang, Y.; Zhao, Y.; Ye, F.; Lin, S.; Deng, W.; Chen, H.; Lei, H.; Zhang, Z.; Luo, M.; Gao, H.; Zheng, Y.; Gong, Y.; Jiang, X.; Xu, Y.; Lv, Q.; Li, D.; Wang, M.; Li, F.; Wang, S.; Wang, G.; Yu, P.; Qu, Y.; Yang, L.; Deng, H.; Tong, A.; Li, J.; Wang, Z.; Yang, J.; Shen, G.; Zhao, Z.; Li, Y.; Luo, J.; Liu, H.; Yu, W.; Yang, M.; Xu, J.; Wang, J.; Li, H.; Wang, H.; Kuang, D.; Lin, P.; Hu, Z.; Guo, W.; Cheng, W.; He, Y.; Song, X.; Chen, C.; Xue, Z.; Yao, S.; Chen, L.; Ma, X.; Chen, S.; Gou, M.; Huang, W.; Wang, Y.; Fan, C.; Tian, Z.; Shi, M.; Wang, F.S.; Dai, L.; Wu, M.; Li, G.; Wang, G.; Peng, Y.; Qian, Z.; Huang, C.; Lau, J.Y.N.; Yang, Z.; Wei, Y.; Cen, X.; Peng, X.; Qin, C.; Zhang, K.; Lu, G.; Wei, X. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature, 2020, 586(7830), 572-577.
[http://dx.doi.org/10.1038/s41586-020-2599-8] [PMID: 32726802]

Dai, L.; Zheng, T.; Xu, K.; Han, Y.; Xu, L.; Huang, E.; An, Y.; Cheng, Y.; Li, S.; Liu, M.; Yang, M.; Li, Y.; Cheng, H.; Yuan, Y.; Zhang, W.; Ke, C.; Wong, G.; Qi, J.; Qin, C.; Yan, J.; Gao, G.F. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell, 2020, 182(3), 722-733.e11.
[http://dx.doi.org/10.1016/j.cell.2020.06.035] [PMID: 32645327]

Walls, A.C.; Fiala, B.; Schäfer, A.; Wrenn, S.; Pham, M.N.; Murphy, M.; Tse, L.V.; Shehata, L.; O’Connor, M.A.; Chen, C.; Navarro, M.J.; Miranda, M.C.; Pettie, D.; Ravichandran, R.; Kraft, J.C.; Ogohara, C.; Palser, A.; Chalk, S.; Lee, E.C.; Guerriero, K.; Kepl, E.; Chow, C.M.; Sydeman, C.; Hodge, E.A.; Brown, B.; Fuller, J.T.; Dinnon, K.H., III; Gralinski, L.E.; Leist, S.R.; Gully, K.L.; Lewis, T.B.; Guttman, M.; Chu, H.Y.; Lee, K.K.; Fuller, D.H.; Baric, R.S.; Kellam, P.; Carter, L.; Pepper, M.; Sheahan, T.P.; Veesler, D.; King, N.P. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell, 2020, 183(5), 1367-1382.e17.
[http://dx.doi.org/10.1016/j.cell.2020.10.043] [PMID: 33160446]

Lee, W.S.; Wheatley, A.K.; Kent, S.J.; DeKosky, B.J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat. Microbiol., 2020, 5(10), 1185-1191.
[http://dx.doi.org/10.1038/s41564-020-00789-5] [PMID: 32908214]

Wang, J.; Wen, Y.; Zhou, S.H.; Zhang, H.W.; Peng, X.Q.; Zhang, R.Y.; Yin, X.G.; Qiu, H.; Gong, R.; Yang, G.F.; Guo, J. Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces potent immunity against SARS-CoV-2 and its variants of concern. J. Med. Chem., 2022, 65(3), 2558-2570.
[http://dx.doi.org/10.1021/acs.jmedchem.1c02000] [PMID: 35073081]

Nag, A.; Banerjee, R.; Paul, S.; Kundu, R. Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study. Comput. Biol. Med., 2022, 146, 105552.
[http://dx.doi.org/10.1016/j.compbiomed.2022.105552] [PMID: 35508082]

Han, P.; Li, L.; Liu, S.; Wang, Q.; Zhang, D.; Xu, Z.; Han, P.; Li, X.; Peng, Q.; Su, C.; Huang, B.; Li, D.; Zhang, R.; Tian, M.; Fu, L.; Gao, Y.; Zhao, X.; Liu, K.; Qi, J.; Gao, G.F.; Wang, P. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell, 2022, 185(4), 630-640.e10.
[http://dx.doi.org/10.1016/j.cell.2022.01.001] [PMID: 35093192]

Bahadur Gurung, A.; Ajmal Ali, M.; Elshikh, M.S.; Aref, I.; Amina, M.; Lee, J. An in silico approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 omicron inhibitors. Saudi J. Biol. Sci., 2022, 29(6), 103297.
[http://dx.doi.org/10.1016/j.sjbs.2022.103297] [PMID: 35475118]

Vardhan, S.; Sahoo, S.K. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19. Comput. Biol. Med., 2020, 124, 103936.
[http://dx.doi.org/10.1016/j.compbiomed.2020.103936] [PMID: 32738628]

Bae, J.R.; Park, W.H.; Suh, D.H.; No, J.H.; Kim, Y.B.; Kim, K. Role of limonin in anticancer effects of Evodia rutaecarpa on ovarian cancer cells. BMC Complement. Med. Therap., 2020, 20(1), 94.
[http://dx.doi.org/10.1186/s12906-020-02890-y] [PMID: 32197606]

Fan, S.; Zhang, C.; Luo, T.; Wang, J.; Tang, Y.; Chen, Z.; Yu, L. Limonin: A Review of Its Pharmacology, Toxicity, and Pharmacokinetics. Molecules, 2019, 24(20), 3679.
[http://dx.doi.org/10.3390/molecules24203679] [PMID: 31614806]

Yang, R.; Yu, H.; Chen, J.; Zhu, J.; Song, C.; Zhou, L.; Sun, Y.; Zhang, Q. Limonin Attenuates LPS-Induced Hepatotoxicity by Inhibiting Pyroptosis via NLRP3/Gasdermin D Signaling Pathway. J. Agric. Food Chem., 2021, 69(3), 982-991.
[http://dx.doi.org/10.1021/acs.jafc.0c06775] [PMID: 33427450]

Vardhan, S.; Sahoo, S.K. Computational studies on the interaction of SARS-CoV-2 Omicron SGp RBD with human receptor ACE2, limonin and glycyrrhizic acid. Comput. Biol. Med., 2022, 144, 105367.
[http://dx.doi.org/10.1016/j.compbiomed.2022.105367] [PMID: 35247766]

Santos Nascimento, I.J.; Silva-Júnior, E.F.; Aquino, T.M. Repurposing FDA-approved drugs targeting SARS-CoV2 3CL pro: A Study by applying virtual screening, molecular dynamics, MM-PBSA calculations and covalent docking. Lett. Drug Des. Discov., 2022, 19(7), 637-653.
[http://dx.doi.org/10.2174/1570180819666220106110133]

Ullrich, S.; Nitsche, C. The SARS-CoV-2 main protease as drug target. Bioorg. Med. Chem. Lett., 2020, 30(17), 127377.
[http://dx.doi.org/10.1016/j.bmcl.2020.127377] [PMID: 32738988]

Qiao, J.; Li, Y.-S.; Zeng, R.; Liu, F.-L.; Luo, R.-H.; Huang, C.; Wang, Y.-F.; Zhang, J.; Quan, B.; Shen, C.; Mao, X.; Liu, X.; Sun, W.; Yang, W.; Ni, X.; Wang, K.; Xu, L.; Duan, Z.-L.; Zou, Q.-C.; Zhang, H.-L.; Qu, W.; Long, Y.-H.-P.; Li, M.-H.; Yang, R.-C.; Liu, X.; You, J.; Zhou, Y.; Yao, R.; Li, W.-P.; Liu, J.-M.; Chen, P.; Liu, Y.; Lin, G.-F.; Yang, X.; Zou, J.; Li, L.; Hu, Y.; Lu, G.-W.; Li, W.-M.; Wei, Y.-Q.; Zheng, Y.-T.; Lei, J.; Yang, S. SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model. Science, 2021, 371(6536), 1374-1378.

Dampalla, C.S.; Zheng, J.; Perera, K.D.; Wong, L.Y.R.; Meyerholz, D.K.; Nguyen, H.N.; Kashipathy, M.M.; Battaile, K.P.; Lovell, S.; Kim, Y.; Perlman, S.; Groutas, W.C.; Chang, K.O. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. Proc. Natl. Acad. Sci. USA, 2021, 118(29), e2101555118.
[http://dx.doi.org/10.1073/pnas.2101555118] [PMID: 34210738]

Owen, D.R.; Allerton, C.M.N.; Anderson, A.S.; Aschenbrenner, L.; Avery, M.; Berritt, S.; Boras, B.; Cardin, R.D.; Carlo, A.; Coffman, K.J.; Dantonio, A.; Di, L.; Eng, H.; Ferre, R.; Gajiwala, K.S.; Gibson, S.A.; Greasley, S.E.; Hurst, B.L.; Kadar, E.P.; Kalgutkar, A.S.; Lee, J.C.; Lee, J.; Liu, W.; Mason, S.W.; Noell, S.; Novak, J.J.; Obach, R.S.; Ogilvie, K.; Patel, N.C.; Pettersson, M.; Rai, D.K.; Reese, M.R.; Sammons, M.F.; Sathish, J.G.; Singh, R.S.P.; Steppan, C.M.; Stewart, A.E.; Tuttle, J.B.; Updyke, L.; Verhoest, P.R.; Wei, L.; Yang, Q.; Zhu, Y. An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19. Science., 2021, 374(6575), 6575-1593.

Greasley, S.E.; Noell, S.; Plotnikova, O.; Ferre, R.; Liu, W.; Bolanos, B.; Fennell, K.; Nicki, J.; Craig, T.; Zhu, Y.; Stewart, A.E.; Steppan, C.M. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. J. Biol. Chem., 2022, 298(6), 101972.
[http://dx.doi.org/10.1016/j.jbc.2022.101972] [PMID: 35461811]

Vangeel, L.; Chiu, W.; De Jonghe, S.; Maes, P.; Slechten, B.; Raymenants, J.; André, E.; Leyssen, P.; Neyts, J.; Jochmans, D. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res., 2022, 198, 105252.
[http://dx.doi.org/10.1016/j.antiviral.2022.105252] [PMID: 35085683]

Li, P.; Wang, Y.; Lavrijsen, M.; Lamers, M.M.; de Vries, A.C.; Rottier, R.J.; Bruno, M.J.; Peppelenbosch, M.P.; Haagmans, B.L.; Pan, Q. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res., 2022, 32(3), 322-324.
[http://dx.doi.org/10.1038/s41422-022-00618-w] [PMID: 35058606]

Paulo, A.; Gomes, E.T.; Houghton, P.J. New Alkaloids from Cryptolepis sanguinolenta. J. Nat. Prod., 1995, 58(10), 1485-1491.
[http://dx.doi.org/10.1021/np50124a002]

Cimanga, K.; De Bruyne, T.; Pieters, L.; Claeys, M.; Vlietinck, A. New alkaloids from Cryptolepis sanguinolenta. Tetrahedron Lett., 1996, 37(10), 1703-1706.
[http://dx.doi.org/10.1016/0040-4039(96)00112-8]

Ambros, R.; Angerer, S.V.; Wiegrebe, W. Synthesis and antitumor activity of methoxy-indolo[2,1-a]isoquinolines. Arch. Pharm., 1988, 321(8), 481-486.
[http://dx.doi.org/10.1002/ardp.19883210811] [PMID: 3223806]

Saundane, A.R.; Ranganath, S.H.; Prayagraj, G.; Rudresh, K.; Satyanarayana, N.D. Synthesis and Pharmacological Studies of Some New 11H- Indolo[3,2-C] Isoquinolin-5-Ylthio)Acetyl Thiosemicarbazide Andits Derivatives. Orient. J. Chem., 1998, 14, 251-254.

Verma, V.A.; Saundane, A.R.; Shamrao, R.; Meti, R.S.; Shinde, V.M. Novel indolo [3,2-c]isoquinoline-5-one-6-yl [1,2,4]triazolo [3,4-b] [1,3,4]thiadiazole analogues: Design, synthesis, anticancer activity, docking with SARS-CoV-2 Omicron protease and MESP/TD-DFT approaches. J. Mol. Struct., 2022, 1264, 133153.
[http://dx.doi.org/10.1016/j.molstruc.2022.133153] [PMID: 36532891]

Unoh, Y.; Uehara, S.; Nakahara, K.; Nobori, H.; Yamatsu, Y.; Yamamoto, S.; Maruyama, Y.; Taoda, Y.; Kasamatsu, K.; Suto, T.; Kouki, K.; Nakahashi, A.; Kawashima, S.; Sanaki, T.; Toba, S.; Uemura, K.; Mizutare, T.; Ando, S.; Sasaki, M.; Orba, Y.; Sawa, H.; Sato, A.; Sato, T.; Kato, T.; Tachibana, Y. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem., 2022, 65(9), 6499-6512.
[http://dx.doi.org/10.1021/acs.jmedchem.2c00117] [PMID: 35352927]

Ahn, D.G.; Choi, J.K.; Taylor, D.R.; Oh, J.W. Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA templates. Arch. Virol., 2012, 157(11), 2095-2104.
[http://dx.doi.org/10.1007/s00705-012-1404-x] [PMID: 22791111]

Uengwetwanit, T.; Chutiwitoonchai, N.; Wichapong, K.; Karoonuthaisiri, N. Identification of novel SARS-CoV-2 RNA dependent RNA polymerase (RdRp) inhibitors: From in silico screening to experimentally validated inhibitory activity. Comput. Struct. Biotechnol. J., 2022, 20, 882-890.
[http://dx.doi.org/10.1016/j.csbj.2022.02.001] [PMID: 35136534]

de Farias, S.T.; dos Santos, Junior, A.P.; Rêgo, T.G.; José, M.V. Origin and Evolution of RNA-Dependent RNA Polymerase. Front. Genet., 2017, 8, 125.
[http://dx.doi.org/10.3389/fgene.2017.00125] [PMID: 28979293]

Hillen, H.S.; Kokic, G.; Farnung, L.; Dienemann, C.; Tegunov, D.; Cramer, P. Structure of replicating SARS-CoV-2 polymerase. Nature, 2020, 584(7819), 154-156.
[http://dx.doi.org/10.1038/s41586-020-2368-8] [PMID: 32438371]

Painter, W.P.; Holman, W.; Bush, J.A.; Almazedi, F.; Malik, H.; Eraut, N.C.J.E.; Morin, M.J.; Szewczyk, L.J.; Painter, G.R. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob. Agents Chemother., 2021, 65(5), e02428-e20.
[http://dx.doi.org/10.1128/AAC.02428-20] [PMID: 33649113]

Agostini, M.L.; Pruijssers, A.J.; Chappell, J.D.; Gribble, J.; Lu, X.; Andres, E.L.; Bluemling, G.R.; Lockwood, M.A.; Sheahan, T.P.; Sims, A.C.; Natchus, M.G.; Saindane, M.; Kolykhalov, A.A.; Painter, G.R.; Baric, R.S.; Denison, M.R. Small-Molecule Antiviral β- D-N4 -Hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol., 2019, 93(24), e01348-e19.
[http://dx.doi.org/10.1128/JVI.01348-19] [PMID: 31578288]

Painter, G.R.; Bowen, R.A.; Bluemling, G.R.; DeBergh, J.; Edpuganti, V.; Gruddanti, P.R.; Guthrie, D.B.; Hager, M.; Kuiper, D.L.; Lockwood, M.A.; Mitchell, D.G.; Natchus, M.G.; Sticher, Z.M.; Kolykhalov, A.A. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res., 2019, 171, 104597.
[http://dx.doi.org/10.1016/j.antiviral.2019.104597] [PMID: 31494195]

Kamal, L.; Ramadan, A.; Farraj, S.; Bahig, L.; Ezzat, S. The pill of recovery; Molnupiravir for treatment of COVID-19 patients; A systematic review. Saudi Pharm. J., 2022, 30(5), 508-518.
[http://dx.doi.org/10.1016/j.jsps.2022.03.002] [PMID: 35287313]

Rosenke, K.; Okumura, A.; Lewis, M.C.; Feldmann, F.; Meade-White, K.; Bohler, W.F.; Griffin, A.; Rosenke, R.; Shaia, C.; Jarvis, M.A.; Feldmann, H. Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model. JCI Insight, 2022, 7(13), e160108.
[http://dx.doi.org/10.1172/jci.insight.160108] [PMID: 35579953]

Beigel, J.H.; Tomashek, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S.; Lopez de Castilla, D.; Finberg, R.W.; Dierberg, K.; Tapson, V.; Hsieh, L.; Patterson, T.F.; Paredes, R.; Sweeney, D.A.; Short, W.R.; Touloumi, G.; Lye, D.C.; Ohmagari, N.; Oh, M.; Ruiz-Palacios, G.M.; Benfield, T.; Fätkenheuer, G.; Kortepeter, M.G.; Atmar, R.L.; Creech, C.B.; Lundgren, J.; Babiker, A.G.; Pett, S.; Neaton, J.D.; Burgess, T.H.; Bonnett, T.; Green, M.; Makowski, M.; Osinusi, A.; Nayak, S.; Lane, H.C. Remdesivir for the treatment of Covid-19 — Final report. N. Engl. J. Med., 2020, 383(19), 1813-1826.
[http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32445440]

Gottlieb, R.L.; Vaca, C.E.; Paredes, R.; Mera, J.; Webb, B.J.; Perez, G.; Oguchi, G.; Ryan, P.; Nielsen, B.U.; Brown, M.; Hidalgo, A.; Sachdeva, Y.; Mittal, S.; Osiyemi, O.; Skarbinski, J.; Juneja, K.; Hyland, R.H.; Osinusi, A.; Chen, S.; Camus, G.; Abdelghany, M.; Davies, S.; Behenna-Renton, N.; Duff, F.; Marty, F.M.; Katz, M.J.; Ginde, A.A.; Brown, S.M.; Schiffer, J.T.; Hill, J.A. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med., 2022, 386(4), 305-315.
[http://dx.doi.org/10.1056/NEJMoa2116846] [PMID: 34937145]

Gomaa, A. Complementary Intervention for COVID-19. Available From: https://www.clinicaltrials.gov/ct2/show/NCT04487964 [Accessed on Jul 11, 2022].

Aarogyam, U. a pilot study on efficacy and safety of ayurveda combination in patients with mild-to-moderate COVID-19. Available From: https://clinicaltrials.gov/ct2/show/NCT04621903 [Accessed on Jul 11, 2022].

Aarogyam, U. Feasibility of ayurveda in patients with mild-tomoderate COVID-19: A community-based participatory research. Available From: https://www.clinicaltrials.gov/ct2/show/NCT04716647 [Accessed on Jul 11, 2022].

Roshni, J.; Vaishali, R.; Ganesh, K.S.; Dharani, N.; Alzahrani, K.J.; Banjer, H.J.; Alghamdi, A.H.; Theyab, A.; Ahmed, S.S.S.J.; Patil, S. Multi-target potential of Indian phytochemicals against SARS-CoV-2: A docking, molecular dynamics and MM-GBSA approach extended to Omicron B.1.1.529. J. Infect. Public Health, 2022, 15(6), 662-669.
[http://dx.doi.org/10.1016/j.jiph.2022.05.002] [PMID: 35617830]